October 22, 2021
Kaken Pharmaceutical said on October 21 that its burn eschar remover KMW-1, which is currently under regulatory review in Japan, met the primary endpoint in a PIII clinical study. The PIII trial is a multicenter, uncontrolled, open-label study that enrolled...read more